---
layout: post
title: "Grünenthal's proprietary NaV 1.8 inhibitor enters clinical development"
date: 2026-02-18T11:24:00+00:00
source: PR Newswire Releases
source_url: https://www.prnewswire.com/news-releases/grunenthals-proprietary-nav-1-8-inhibitor-enters-clinical-development-302691460.html
significance: 7.00
---

<p>AACHEN, Germany, Feb. 18, 2026 /PRNewswire/ -- Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy...</p>

**Source:** [PR Newswire Releases](https://www.prnewswire.com/news-releases/grunenthals-proprietary-nav-1-8-inhibitor-enters-clinical-development-302691460.html)

**Published:** 2026-02-18 11:24:00 +0000

**Significance Score:** 7.00

[View original](https://www.prnewswire.com/news-releases/grunenthals-proprietary-nav-1-8-inhibitor-enters-clinical-development-302691460.html)
